Harpoon Therapeutics, Inc.

NasdaqCM:HARP Stock Report

Market Cap: US$492.3m

Harpoon Therapeutics Dividend

Dividend criteria checks 0/6

Harpoon Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.8%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$1.43
Dividend yield forecast in 3Y0%

Recent dividend updates

No updates

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14
Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28
Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Mar 11
Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics appoints Luke Walker as CMO

Oct 04

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Sep 01

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08
Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if HARP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HARP's dividend payments have been increasing.


Dividend Yield vs Market

Harpoon Therapeutics Dividend Yield vs Market
How does HARP dividend yield compare to the market?
SegmentDividend Yield
Company (HARP)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (HARP)0%

Notable Dividend: Unable to evaluate HARP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HARP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate HARP's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HARP has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.